Azitra, Inc.

Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology, developing therapies based on engineered proteins and topical live biotherapeutic products. The company’s core asset is a proprietary microbial library of roughly 1,500 bacterial strains, which it screens with artificial intelligence and machine learning to identify drug-like molecules and therapeutic candidates. It also uses licensed genetic engineering technology to modify strains that would otherwise be difficult to engineer. Azitra has not begun commercial operations, so its business today is centered on research, preclinical and clinical development, and building a platform that could support future product approvals or licensing deals.

−100,0 %

2.83

2.83

— Azitra, Inc.
%
Clinical dermatology programs0% Lead and pipeline therapeutic candidates intended for skin diseases and precision dermatology indications.
Live biotherapeutic products45% Topical microbiome-based therapies built from engineered or selected bacterial strains.
Recombinant proteins and engineered molecules35% Protein- and peptide-based candidates derived from skin microbes and platform discovery work.
Platform licensing and collaboration20% Potential out-licensing, joint development, and related-party collaboration revenue from the microbial platform and IP.

Azitra’s eventual customers are primarily patients with skin diseases, but the company currently sells no commercial...

  • Dermatology patientsprimary

    Patients with skin diseases targeted by Azitra’s precision dermatology pipeline would use the approved therapies if development succeeds.

  • Dermatologists and healthcare providersprimary

    Specialists would prescribe or recommend the company’s products and are central to commercial adoption in concentrated dermatology indications.

  • Third-party payorssecondary

    Commercial insurers and government programs would determine reimbursement and access for any approved prescription products.

  • Biopharmaceutical partnerssecondary

    Partners may license strains, IP, or enter joint development arrangements to access Azitra’s microbial platform and candidates.

  • Consumer health and cosmeceutical channelsemerging

    Potential future buyers of non-prescription products derived from the platform, if those programs are advanced successfully.

Azitra is headquartered in the United States and plans to build its initial commercial capabilities there if any...

  • •United States is the planned initial commercialization market
  • •Company is headquartered in the U.S. and organized as a Delaware corporation
  • •Commercial buildout is intended to be focused and specialist-driven
  • •Non-U.S. markets may be served through collaborations or licensing
  • •Current geographic exposure is mainly development, regulatory, and trial-related
  • •No meaningful country revenue disclosure was provided in the excerpts

Azitra’s strategy is to convert its microbial discovery platform into a portfolio of precision dermatology assets with...

01
Advance lead dermatology candidatesshort-term

Clinical and regulatory progress is the main path to creating value because the company has no commercial revenue base.

02
Expand the platform pipelinemedium-term

A broader set of candidates increases the chance that at least one asset reaches commercialization or becomes licensable.

03
Monetize through partnerships and licensingmedium-term

Collaborations can reduce capital intensity and create non-dilutive value before full commercialization.

04
Build a focused U.S. commercial modellong-term

A targeted specialist sales approach could be more efficient in concentrated dermatology indications than a broad launch model.

Azitra faces the classic risks of an early-stage biotech with no commercial revenue: clinical failure, regulatory...

critical

Going concern and financing risk

The company has no commercial operations and continues to incur losses, so it must raise additional capital to fund development.

Scope
Operating runway, dilution, and potential delay of programs
Materiality
high
high

Clinical development failure

Lead candidates may not demonstrate sufficient safety or efficacy in preclinical or clinical studies.

Scope
Pipeline value and future approval prospects
Materiality
high
high

Regulatory approval risk

Even promising candidates require FDA approval and may face delays, additional studies, or manufacturing requirements.

Scope
Time to market and commercialization timing
Materiality
high
high

Manufacturing and supply chain dependence

The company relies on third-party manufacturers and suppliers for clinical and future commercial supply.

Scope
Trial delays, cost overruns, and product quality
Materiality
high
medium

Partnering and licensing execution risk

Out-licensing or joint development may take a long time and is outside management’s direct control.

Scope
Non-dilutive funding and platform monetization
Materiality
medium
Research and development expense classification
Can cause quarter-to-quarter volatility in operating losses
Related-party service revenue
Revenue base is immaterial and not recurring
Going concern disclosure
Important for liquidity analysis and financing assumptions
Warrant fair value changes
Can distort comparability of reported earnings
Lease accounting and patent/trademark capitalization
Affects balance sheet presentation and cash flow analysis

Aprea Therapeutics, Inc.

APRE · Pharmaceutical Preparations

Aura Biosciences, Inc.

AURA · Biological Products, (No Diagnostic Substances)

aTYR PHARMA INC

ATYR · Biological Products, (No Diagnostic Substances)

Bicara Therapeutics Inc.

BCAX · Pharmaceutical Preparations

Aspire Biopharma Holdings, Inc.

ASBP · Pharmaceutical Preparations

Centessa Pharmaceuticals plc

Pharmaceutical Preparations

: 11/08/2026